News & Updates

The oral antiviral drug umifenovir, which is used to treat influenza, appears to be beneficial in COVID-19 patients who are asymptomatic or with mild symptoms, with a phase III study showing that the drug is well tolerated and can induce viral clearance within 5 days.

Patients with the coronavirus disease 2019 (COVID-19), even those genetically predisposed to the disease, are not at increased risk of developing atrial fibrillation, and vice versa, a study has found.

A large study conducted in Israel has suggested that the effectiveness of the BNT162b2 vaccine against COVID-19 decreases over time.

Long-term exposure to particulate matter ≤2.5 μm (PM2.5) results in increased admission to hospital for COVID-19, according to a recent study.

A recent Singapore meta-analysis of randomized controlled trials (RCT) has found no clear clinical benefit to using convalescent plasma (CP) for patients with the coronavirus disease 2019 (COVID-19), especially in those with severe disease.

A single injection of tocilizumab is enough to weaken systemic inflammation for up to 7 days in patients with the coronavirus disease 2019 (COVID-19), a recent study suggests.

The coverage of influenza vaccination for Medicare beneficiaries remains poor, reports a study, noting missed opportunities despite availability of vaccines with no copayment. In addition, there are still disparities in vaccination uptake by race/ethnicity.

Adults newly diagnosed with COVID-19 in outpatient settings and enrolled in an automated remote monitoring service are less likely to succumb to the disease potentially due to more frequent telemedicine encounters and earlier presentation to the emergency department (ED), a study has shown.

In patients with the coronavirus disease 2019 (COVID-19), hypertension aggravates the risk of cardiac injury and severe disease phenotype, a recent study has found.

The pan-sarbecovirus monoclonal antibody sotrovimab appears to reduce the risk of COVID-19 disease progression in high-risk patients, according to interim results of the phase III COMET-ICE* trial.